What is Mirus Bio?
Founded in 1995 and headquartered in Madison, Wisconsin, Mirus Bio has established itself as a premier provider of transfection reagents essential for gene therapy, recombinant protein production, and stem cell research. As an original pioneer in the sector, the company bridges the gap between laboratory-scale innovation and commercial-grade manufacturing. By introducing specialized solutions such as the TransIT-VirusGEN GMP Transfection Reagent, Mirus Bio addresses the complex requirements of the cell and gene therapy markets, ensuring that biopharmaceutical developers have the high-performance tools necessary for clinical success and therapeutic development.
How much funding has Mirus Bio raised?
Mirus Bio has raised a total of $893K across 2 funding rounds:
Debt
$350K
Debt
$543K
Debt (2020): $350K with participation from PPP
Debt (2021): $543K led by PPP
Key Investors in Mirus Bio
PPP
Public-Private Partnership
What's next for Mirus Bio?
With this recent infusion of capital, Mirus Bio is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its GMP-compliant manufacturing infrastructure. The company aims to deepen its penetration into the commercial biopharmaceutical sector, where demand for reliable, scalable transfection technology remains at an all-time high. By leveraging its deep expertise in nucleic acid delivery, Mirus Bio is set to enhance its product portfolio, supporting the next generation of gene editing and biotherapeutic protein production. This growth trajectory signals a robust outlook for the company as it continues to serve as a vital link in the global biotechnology supply chain.
See full Mirus Bio company page
